JNS002

Doxorubicin Hydrochloride Liposome Injection · Janssen Pharmaceutical K.K.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNS002, covering 2013-07-04 to 2013-07-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma [Phase 1]

See pricing